|
Synonyms: CDP 6038 | CDP-6038 | CDP6038
Compound class:
Antibody
Comment: Olokizumab (CDP 6038) is a clinical stage anti-IL-6 monoclonal antibody [3], that was designed for potential to treat autoimmune diseases. The antibody blocks assembly of the hexameric IL-6/IL-6 α-receptor/gp130 (IL6ST) complex that is required for signal transduction.
|
| No information available. |
Summary of Clinical Use  |
| UCB Pharma advanced olokizumab into clinical evaluation in rheumatoid arthritis. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01463059 | Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy | Phase 2 Interventional | UCB Pharma | 4 | |
| NCT01262794 | Pharmacokinetic (PK)/Pharmacodynamic (PD), Study of Single-dose Subcutaneous CDP6038 in Healthy Japanese Male Subjects | Phase 1 Interventional | UCB Pharma | 2 | |
| NCT01296711 | Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056 | Phase 2 Interventional | UCB Pharma | 1 | |
| NCT01242488 | Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy | Phase 2 Interventional | UCB Pharma | ||
